OncoMatch/Clinical Trials/NCT06846489
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Is NCT06846489 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Acalabrutinib and Rituximab for mantle cell lymphoma (mcl).
Treatment: Acalabrutinib · Rituximab — This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Histologically confirmed CD20+ mantle cell lymphoma
Required: TP53 wild-type
No TP53 mutation (NGS)
Required: MKI67 expression < 50% (< 50%)
Ki67 < 50%
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-lymphoma treatment
No prior anti-lymphoma treatment
Lab requirements
Blood counts
Adequate organ and bone marrow function during screening
Kidney function
Adequate organ and bone marrow function during screening
Liver function
Adequate organ and bone marrow function during screening
Adequate organ and bone marrow function during screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify